Patient-reported outcomes (PROs) in the double-blind phase 3 trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC for previously treated patients with malignant pleural mesothelioma (MPM).

被引：0

作者：

Gregorc, Vanesa

Bulotta, Alessandra

Vigano, Maria G.

Citterio, Giovanni

Petrella, Giovanna

Brioschi, Elena

Ducceschi, Monika

Gianni, Luca

Colombi, Scialini

Rossoni, Gloria

Salini, Giulia

Savia, Veronica

Lambiase, Antonio

Bordignon, Claudio

机构：

[1] Ist Sci San Raffaele, Dept Oncol, Milan, Italy

[2] MolMed, Milan, Italy

来源：

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.e20077

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e20077

引用

页数：3